The Cost of the 340B Program to States (2026 Refresh)
IQVIA is updating its analysis of the 340B program’s financial impact on state healthcare purchasers, including employers, workers, and managed Medicaid plans. This refreshed study builds on prior research and reflects more than 41 percent growth in the program since the original assessment.
Using drug claims and health plan premium data, the study will deliver a white paper outlining methods, findings, and key insights, along with 50 state summaries to support policymakers and stakeholders evaluating 340B’s impact.
Findings will be released in July 2026.
340B is not free. The cost of 340B to employers can vary drastically across states. Explore the cost of the 340B Program across all 50 states with individual one-page fact sheets. Understand how it affects employers, workers, and government health plans, and what upcoming legislative changes could mean for your state. These one-page fact sheets break down the costs, highlight state-specific trends, and provide valuable insights into the broader implications of 340B utilization nationwide.
Dive into the data and discover how legislative shifts and healthcare policies influence costs at both state and national levels.
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Related solutions
Lower contract management costs and mitigate risk.
Gain high value access and increase the profitability of your brands